Brief: Immunovant Inc Announces Positive Initial IMVT-1402 Phase 1 SAD And 300 Mg Subcutaneous MAD Results
26/09/2023 11:24
Sept 26 (Reuters) - Immunovant Inc IMVT.O :
* IMMUNOVANT INC - ANNOUNCES POSITIVE INITIAL IMVT-1402
PHASE 1
SAD AND 300 MG SUBCUTANEOUS MAD RESULTS
Source text for Eikon: ID:nGNXbgtFvj
Further company coverage: IMVT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immunovant
See all newsU.S. STOCKS ON THE MOVE-Tesla, Blue Owl, Ford
Immunovant falls as drug for thyroid eye disease fails late-stage trials
Immunovant falls as eye disease therapy fails in late-stage studies
Immunovant Q3 net loss smaller than expected
Brief: Immunovant Q3 Net Income USD -110.635 Million Vs. IBES Estimate USD -125.1 Million